Immune cocktail shows promise in early trial for stubborn cancers
NCT ID NCT03388632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new mix of three drugs—IL-15, nivolumab, and ipilimumab—in 31 adults with cancers that no longer respond to standard treatments. The goal was to find the safest dose and see if the combination could help the immune system attack tumors. Participants received the drugs in cycles and were monitored closely for side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can your own immune cells fight advanced cancer?
- Can a radioactive antibody light up hidden cancers on PET scans?
- Blood test may let cancer patients take safe breaks from immunotherapy
- Off-the-Shelf cell therapy takes on Hard-to-Treat cancers
- New drug duo aims to reboot immune attack on Hard-to-Treat cancers